glp 1 and ovarian cancer Among adults with #obesity, use of #GLP-1 receptor agonists was associated with reduced risk of developing several #cancers, including #endometrial, #ovarian, meningioma, compared with those not The dual impact of GLP-1

Role of Obesity in Lipid Management Weight loss plays a critical role in management of lipid profiles for obese and overweight patients

FDA concluded that based on the available evidence, that the supply of semaglutide meets or exceeds current demand, and that, based on our best judgment looking at the available information with its limitations, supply will meet or exceed projected demand. FDA acknowledges in the Declaratory Order that: [E]ven when a shortage is considered resolved, patients and prescribers may still see intermittent localized supply disruptions as products move through the supply chain from the manufacturer and distributors to local pharmacies

Understanding these predispositions can support a more informed conversation with your provider about whether GLP-1 therapy aligns with your biological profile, independent of Medicaid coverage decisions

In previous large-scale clinical trials of GLP-1RAs, 15.2% ( n = 618) of AMPLITUDE-O and 6.1% ( n = 575) of Harmony Outcomes patients used SGLT2is at baseline [18, 20] (Table 1)